DENVER & TAMPA, Fla.– VieCure, a cancer care company with a market leading artificial intelligence, informatics, and clinical decision support platform, announced today a new strategic collaboration with Clarified Precision Medicine which will make precision oncology more accessible for patients and community oncologists. In recent years there has been a large shift towards the use of cancer treatments which respond specifically to the molecular profile of the cancer (e.g., genomic data). These data are complex, considerable, and difficult to access at the community oncology level. This has highlighted a critical absence of medical guidance for both providers and payors and has motivated VieCure and Clarified Precision Medicine to work together to provide oncologists and their patients with clear, usable interpretations of any commercial comprehensive molecular profiling test along with a ranked list of treatment options which are reviewed by nationally recognized precision oncology experts. This partnership will also facilitate objective, third-party clinical review to assist a payor with prior authorization or an approval decision.
VieCure will fully integrate the Clarified Precision Medicine Somatic and Germline Clinical Consultation process within its A.I. platform and offer community oncologists with streamlined access to Clarified’s nationally recognized test interpretation team. These professionals will function as elastic supply for the clinical providers on the ground who are working tirelessly everyday to help cancer patients and offer them with the best patient specific options possible. Clarified Precision Medicine has also developed additional tools which help providers manage toxicities, optimize supportive care, and improve overall clinical efficiency.
“In recent years, we have witnessed the introduction of improved access to an individual’s tax preparation to the point that tax experts are now available via the tax software. The Viecure-Clarified partnership offers a precision oncology expert version, where elite, expert precision medicine guidance can be accessed while using the Viecure clinical decision support platform. We are excited about embedding our expertise to further accelerate the adoption of precision oncology and help more patients and providers over the next several years,” said Dr. Howard McLeod, a Nationally-recognized Precision Oncology expert.
